Light therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dry AMD (not the wet type) at an early or moderate stage (AREDS grade 2 or 3).
- Your vision is better than 20/80 (measured on an eye chart).
- You do not have epilepsy, any active herpes infection, dense cataract, or other serious eye diseases.
- You are not pregnant, and you have no major neurological or psychiatric conditions.
- You can understand English or Italian and follow the study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a light-based treatment (photobiomodulation) can help people with dry age-related macular degeneration in one eye. Because one eye is treated while the other eye has a different type of AMD in the study design, eligibility depends on which type of AMD you have in each eye.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
This study tests a device that uses gentle electrical stimulation to try to improve vision in people with early to intermediate dry age-related macular degeneration. It could help slow vision loss and improve daily function.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.